Stock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition
Stock Track
Yesterday
Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.
Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.
The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.